RT Journal Article
SR Electronic
T1 Examination of Medication Use Patterns by Age Group, Comorbidity, and Month in COVID-19 Positive Patients in a Large State-wide Health System During the Pandemic in 2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.15.21259539
DO 10.1101/2021.07.15.21259539
A1 Watanabe, Jonathan H.
A1 Kwon, Jimmy
A1 Nan, Bin
A1 Abeles, Shira R.
A1 Mehta, Sanjay R.
YR 2021
UL http://medrxiv.org/content/early/2021/07/21/2021.07.15.21259539.abstract
AB Objectives Main objective was to systematically determine most frequently used medications among COVID-19 patients overall and by hospitalization status. Secondary objective was to measure use patterns of medications considered potential therapeutic optionsDesign Retrospective cohort study.Setting The five academic medical centers of University of California Health.Participants University of California COVID Research Data Set (UC CORDS) patients between March 10, 2020 and December 31, 2020.Exposure(s) Confirmed COVID-19 positive by SARS-CoV-2 nucleic acid amplification.Main Outcome(s) and Measure(s) Main outcomes were percentages of patients prescribed medications, overall, by age group, and by comorbidity based on hospitalization status. Use percentage by month of COVID-19 diagnosis was measured. Cumulative count of potential therapeutic options was measured over time.Results Dataset included 22897 unique patients with COVID-19 (mean [SD] age, 42.4 [20.4] years; 12154 [53%] female). Among the sample, 6326 28%) were non-Hispanic White, 8475 (37%) were Hispanic, 1562 (7%) Asian, and 1313 (6%) Black. A COVID-related hospitalization occurred in 3546 patients. Of the hospitalized patients, more than 30% had baseline comorbidities of hypertension (48%), hyperlipidemia (37%), and type 2 diabetes (35%). Most frequently used medications in patients overall were acetaminophen (21.2%), albuterol (14.9%), ondansetron (13.9%), and enoxaparin (10.8%). Medications used were generally similar across ages and comorbidities. Prior to May, dexamethasone was rarely used, with well under 50 COVID-19 patients that had been hospitalized to that point receiving the medication. By mid-August, more than 500 patients to that point had received dexamethasone. Hydroxychloroquine use effectively halted in COVID-19 hospitalized patients after May. Throughout the period of March to December 2020, enoxaparin was used in the most patients to that point at any instance. By mid-December, more than 2000 in the analysis cohort of hospitalized patients had received enoxaparin.Conclusions and Relevance In this retrospective cohort study, across age and comorbidity groups, predominant utilization was for supportive care therapy. Dexamethasone and remdesivir experienced large increases in use. Conversely, hydroxychloroquine and azithromycin use markedly dropped. Medication utilization rapidly shifted towards more evidence-concordant treatment of patients with COVID-19 as rigorous study findings emerged.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was utilized for this analysis.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of California COVID-19 Research Data Set (UC CORDS) was operationalized by University of California Health as non-human subjects research limited data set and analyses are considered institutional review board exempt (Category 4) by determination of the 5 University of California IRB Directors overseeing University of California Health on May 8, 2020 for IRB Protocol 20-30889.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe extracted dataset used for this retrospective analysis is maintained on secured servers and is only available for analysis via virtual desktop maintained and supported by the University of California Irvine Health that manages access to the University of California COVID-19 Research Data Set (UC CORDS).